Invex Therapeutics (ASX:IXC) EBIT per Share: A$-0.02 (TTM As of Dec. 2025)


What is Invex Therapeutics EBIT per Share?

Invex Therapeutics ASX:IXC -9.09% EBIT per Share is A$-0.02 as of Dec. 2025. The stock has 1 warning sign investors should review. Among 1,182 Biotechnology companies, Invex Therapeutics ranks better than 78% on this metric.

Invex Therapeutics's EBIT per Share for the six months ended in Dec. 2025 was A$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.

During the past 3 years, the average EBIT per Share Growth Rate was 38.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was 15.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Invex Therapeutics's EBIT per Share or its related term are showing as below:

ASX:IXC' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -25   Med: -10.9   Max: 38.5
Current: 38.5

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Invex Therapeutics was 38.50% per year. The lowest was -25.00% per year. And the median was -10.90% per year.

ASX:IXC's 3-Year EBIT Growth Rate is ranked better than
78% of 1182 companies
in the Biotechnology industry
Industry Median: 15.45 vs ASX:IXC: 38.50

Invex Therapeutics's EBIT for the six months ended in Dec. 2025 was A$-0.84 Mil.

Invex Therapeutics  (ASX:IXC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Invex Therapeutics EBIT per Share Related Terms

Invex Therapeutics EBIT per Share Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics EBIT per Share Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT per Share
Get a 7-Day Free Trial -0.03 -0.06 -0.12 -0.05 -0.01

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.01 -0.01 -0.01 -0.01

Invex Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Invex Therapeutics's EBIT per Share for the fiscal year that ended in Jun. 2025 is calculated as

EBIT per Share(A: Jun. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.951/75.154
=-0.01

Invex Therapeutics's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.843/75.154
=-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of A$-0.02 mean?
Invex Therapeutics (ASX:IXC) has a EBIT per Share of A$-0.02 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Invex Therapeutics and its competitors. According to the industry distribution chart, Invex Therapeutics ranks #260 out of 1182 companies in the Biotechnology industry, placing it in the top 22%.
Is Invex Therapeutics' EBIT per Share too high?
Invex Therapeutics' current EBIT per Share is A$-0.02. Based on the distribution chart, Invex Therapeutics ranks #260 out of 1182 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Invex Therapeutics' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Invex Therapeutics ranks #260 out of 1182 companies for EBIT per Share. This places Invex Therapeutics in the top 22% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,182 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Invex Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invex Therapeutics's current EBIT per Share is A$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current EBIT per Share of A$-0.02. The current EBIT per Share is A$-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current EBIT per Share is A$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.